Evidence map›Paper›PMID 31554033›Full record

ArticleThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi2019

Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis.

Yu Kyung Jun, Jaeyoung Chun, Eun Ae Kang, Hyun Jung Lee, Jong Pil Im, Joo Sung Kim

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yu Kyung JunDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Jaeyoung ChunDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.ORCID http://orcid.org/0000-0002-4212-0380
Eun Ae KangDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Hyun Jung LeeDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Jong Pil ImDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Joo Sung KimDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Seoul National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-tumor necrosis factor (anti-TNF) is an effective biological agent for the treatment of moderate-to-severe active ulcerative colitis (UC) refractory to conventional therapy. On the other hand, anti-TNF therapy is strongly associated with a potential risk of tuberculosis (TB). Active TB is a critical complication that makes it difficult to treat patients who require anti-TNF for the treatment of UC refractory to conventional therapy. Based on the clinical guidelines, patients with inflammatory bowel disease (IBD) are strongly recommended to screen for latent TB before anti-TNF administration. Considering the possibility of active or reactivated TB related to anti-TNF therapy, all patients with IBD should be monitored closely for TB during anti-TNF therapy, irrespective of the screening results for latent TB. In particular, the risk of anti-TNF-related multidrug-resistant TB (MDR-TB) in patients with IBD has not been elucidated. This paper reports the first case of disseminated MDR-TB that developed in a UC patient receiving infliximab despite the negative evaluation for latent TB screening.

Indexed as

AdultAntibodies, MonoclonalAntitubercular AgentsColitis, UlcerativeColonoscopyDrug Therapy, CombinationFemaleHumansInfliximabLatent TuberculosisLymph NodesTomography, X-Ray ComputedTuberculosisTuberculosis, Multidrug-ResistantAntibodies, MonoclonalAntitubercular AgentsInfliximabColitisInflammatory bowel diseasesInfliximabmultidrug-resistantTuberculosisulcerative

Identifiers

PMID31554033
PMCPMC12285780
OpenAlexW2978130165

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.